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Transdifferentiation of α- to β-cells is enhanced in FSTL3 KO mice. 
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Both type 1 and type 2 diabetes involve loss of functional pancreatic β-cells which is driving research into 
potential replacement sources.  Expansion of functional β-cell mass, such as through induction of β−cell 
neogenesis or through transdifferentiation of α−cells into functional β−cells represent appealing therapeutic 
solutions to restoring glucose control.  To date, however, these processes have been induced through genetic 
manipulation or severe pancreatic injury.  It remains to be determined whether transdifferentiation or 
neogenesis contribute to functional β-cell mass under normal physiological conditions and/or contribute to β-
cell expansion and how these processes are regulated. 
 
We have reported that inactivation of the activin antagonist follistatin like-3 (FSTL3) resulted in a 2-fold 
increase in mean islet size with an enlarged β-cell component.  We hypothesized that the β-cell expansion 
resulted from accelerated α- to β-cell transdifferentiation that was induced by the enhanced activin 
bioavailability of the FSTL3 KO mouse.  We first demonstrated that activin suppressed important α-cell gene 
expression and promoted β-cell gene expression in α- and β-cell lines.  We then used cell sorting based on 
natural fluorescence of α- and β-cells to achieve >95% enrichment of these cell populations.  Activin treatment 
of these primary cells also suppressed α-cell gene expression including ARX.  To explore whether activin had 
this effect in vivo, we used lineage tracing to label α-cells with YFP using Gluc-Cre/YFP mice crossed with 
FSTL3 KO mice.  Cell sorting identified 2 additional populations, YFP labeled α-cells and YFP labeled β-cells 
with the number of YFP+Ins+ cells increased in FSTL3 KO islets compared to WT.  These results suggest that 
α- to β-cell transdifferentiation occurs in the absence of genetic drivers or injury, that this process is increased 
in FSTL3 KO mice, and that activin may promote transdifferentiation to increase β-cell mass. 
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